Reference health
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
30/30 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 30 checked references that resolve
resolves10.1002/art.502
How important are T cells in chronic rheumatoid synovitis?: II. T cell‐independent mechanisms from beginning to end
resolves10.1046/j.1365-2567.1999.00772.x
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
resolves10.1056/NEJM197804202981602
Association of the B-Cell Alloantigen DRw4 with Rheumatoid Arthritis
resolves10.1084/jem.173.2.487
Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells.
resolves10.1002/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO;2-G
Induction of tumor necrosis factor α production by adhered human monocytes: A key role for Fcγ receptor type IIIA in rheumatoid arthritis
resolves10.1046/j.1365-2567.1998.00491.x
Differential distribution of FcγRIIIa in normal human tissues and co‐localization with DAF and fibrillin‐1: implications for imm_unological microenvironments
resolves10.1093/rheumatology/40.2.205
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
resolves10.1212/WNL.52.8.1701
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
resolves10.1182/blood.V98.4.952
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
resolves10.1136/ard.61.10.883
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
resolves10.1182/blood.V83.2.435.435
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
resolves10.1200/JCO.1997.15.10.3266
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
resolves10.1200/JCO.1998.16.8.2825
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
resolves10.1034/j.1399-3089.2001.008003157.x
Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of
anti‐αGal antibody
resolves10.1016/S0307-742X(21)00604-4
IgG Rheumatoid Factors and Self-association of These Antibodies
resolves10.1002/1529-0131(200101)44:1<41::AID-ANR6>3.0.CO;2-0
Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis
resolves10.4049/jimmunol.166.3.1492
The Human Endoplasmic Reticulum Molecular Chaperone BiP Is an Autoantigen for Rheumatoid Arthritis and Prevents the Induction of Experimental Arthritis
resolves10.1002/art.1780310302
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
resolves10.1002/art.1780380602
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
resolves10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy
resolves10.1016/S1040-8428(01)00130-5
Rituximab: perspective on single agent experience, and future directions in combination trials
resolves10.1200/JCO.2000.18.17.3135
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
resolves10.1016/S0140-6736(01)06573-4
Treatment of childhood autoimmune haemolytic anaemia with rituximab
resolves10.1111/j.1699-0463.1997.tb00567.x
TNF blockade in rheumatoid arthritis: Implications for therapy and pathogenesis
The 4 references without a DOI — listed, not checked
no DOI — not checkedAn open study of B‐lymphocyte depletion in systemic lupus erythematosus
no DOI — not checkedCHOP plus rituximab chemoimmunotherapy of indolent B‐lymphocyte lymphoma
no DOI — not checkedRoutine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity and predictive value for rheumatoid arthritis
no DOI — not checkedThe use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/art.11181"><img src="https://citestamp.com/citestamped/10.1002/art.11181/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/art.11181)